Sotiris Veranis, Muthu Sathish, Gary Matt, Cho Sam, Kato So, Lewis Stephen J, Kim Ho-Joong, Wang Jeffrey, Jain Amit, Yoon S Tim
Department of Neurosurgery, General Air Force General Staff Hospital, Athens, Greece.
Orthopaedic Research Group, Coimbatore, Tamil Nadu, India.
World Neurosurg X. 2024 Sep 26;24:100397. doi: 10.1016/j.wnsx.2024.100397. eCollection 2024 Oct.
Cross-sectional study with systematic review of literature.
There is an increasing interest in the topical use of antibiotics to prevent infection following spine surgery. To extend the antibiotic coverage to the gram-negative spectrum, the usage of tobramycin powder is being considered. We surveyed to analyze the current practice preference on the use of topical tobramycin in lumbar spine surgery and also aimed to analyze the literature for current evidence on the same.
A multinational cross-sectional survey was conducted among AO Spine members worldwide to understand the use of topical tobramycin in 1 or 2-level open lumbar fusion surgeries. Also, an independent systematic review of four scientific databases (PubMed, Scopus, clinicaltrials.gov, Web of Science) was performed by two authors to identify relevant articles in adherence to the preferred reporting in systematic reviews and meta-analysis (PRISMA) guidelines. Studies reporting the usage of tobramycin in lumbar spine surgeries were included for analysis.
Among the 231 participating surgeons, only 1.7 %( = 4) reported utilizing tobramycin in 1 or 2-level open lumbar fusion surgery. Upon systematic review of the literature, two studies with 484 patients were included for analysis. With the usage of tobramycin as a topical antibiotic powder, both studies noted a reduction in the incidence of infection with change in the spectrum of infective organisms.
Topical Tobramycin is not the commonly preferred topical antibiotic to prevent SSI among spine surgeons worldwide. There is a lack of sufficient evidence to support the routine use of topical tobramycin in lumbar spine surgery.
横断面研究并对文献进行系统综述。
脊柱手术后局部使用抗生素预防感染的关注度日益增加。为了将抗生素覆盖范围扩大到革兰氏阴性菌谱,正在考虑使用妥布霉素粉末。我们进行调查以分析目前在腰椎手术中使用局部妥布霉素的实践偏好,并旨在分析相关文献以获取关于此的现有证据。
在全球范围内对AO脊柱成员进行了一项跨国横断面调查,以了解在1或2节段开放性腰椎融合手术中局部妥布霉素的使用情况。此外,由两位作者对四个科学数据库(PubMed、Scopus、clinicaltrials.gov、Web of Science)进行了独立的系统综述,以按照系统综述和Meta分析的首选报告(PRISMA)指南识别相关文章。纳入报告在腰椎手术中使用妥布霉素的研究进行分析。
在231名参与调查的外科医生中,只有1.7%(n = 4)报告在1或2节段开放性腰椎融合手术中使用了妥布霉素。经对文献进行系统综述,纳入两项共484例患者的研究进行分析。使用妥布霉素作为局部抗生素粉末时,两项研究均指出感染发生率降低,且感染微生物谱发生了变化。
在全球脊柱外科医生中,局部妥布霉素并非预防手术部位感染最常用的局部抗生素。缺乏足够证据支持在腰椎手术中常规使用局部妥布霉素。